TOMORROW BEGINS TONIGHT.
Hibernate's Pilot Studies
Hibernate conducted pilot studies with a multitude of participants through Upwards Labs in Hartford, CT in the fall of 2020. Although we were still living with the pandemic, Hibernate was able to work with over 40 individuals whom provided valuable feedback on their Hibernate experience over several weeks.
These individuals were employees of Upwards Labs' Corporate Partners: Priority Life Care, Stanley Healthcare, UnitedHealthcare, Aetna/ CVS, Accenture, and Nassau Re. Data was collected on the sleep habits, customer experience, quality of sleep pre and post Hibernate use. We also recieved valuable feedback on the Hibernate App.
The Hibernate pilot studies will also be beneficial to our advisors and corporate partners [Aetna/CVS, Cigna, and Stanley Healthcare] to assist with scoping a B2B model, clinical applications, and a commercial launch in 2023.
Hibernate participated in the Fall Cohort 2020 piloting program at Upward Labs in Hartford, CT.
Upward Labs is a CT based Venture Fund that developed the ideal ecosystem to fast-track AgeTech and PropTech startups in the US. The program matches each startup with decision makers from major Fortune 100 and 500 companies that dominate these industries.
The startups and their corporate advisers work together for six months to first identify the most commercializable use cases and then test them in the Lab’s numerous sandbox buildings and facilities. As the pilots deliver data and results, the Lab and its advisers work with the startups to refine their product and offering, thus enabling rapid growth and commercial traction.
Hibernate Partnerships
Hibernate has partnered with the following independent groups to assist with pilot studies.
Additional Hibernate Partnerships
Dr. Jason Carter of Montana State University just concluded their first double blind sleep study with Hibernate.
The protocol utilized a randomized, double-blind, crossover design. Participants who met eligibility criteria were randomly assigned to either the control (N=8) or treatment (N=7) condition first. Each condition consisted of polysomnography (PSG) monitoring, and the Deep Sleep Boost (DSB) was only on with one of the naps (i.e., treatment session). Following at least one-day washout, participants participated in the opposite condition as depicted.
-
Majority experienced positive impact on SWS. As hypothesized, the majority of the sample experienced increased SWS during DSB condition (see Figure 7 and Table 4). Moreover, there were some trends toward increased TST and reduced WASO during DSB
Note: Sleep statistics of participants with slow wave sleep in both conditions. TST, total sleep time; WASO, wake after sleep onset; SWS, slow wave sleep; REM, rapid eye movement; N1, stage 1 sleep; N2, stage 2 sleep.
Hibernate's Second Double Blind Clinical Study will conclude in November 2022. The current data shows a positive affect of both Deep Sleep and HRV when Hibernate is active. We look forward to publishing the results of these studies in a Peer Review Journal in January 2023.
